My watch list  

20 Current news of Affitech


You can refine your search further. Select from the filter options on the left to narrow down your results.

Affitech A/S completes AT001/r84 preclinical package milestone in R&D agreement with IBC Generium


Affitech A/S announced that the Company has received 2.5 million Euro in milestone payment from IBC Generium. The payment is related to the delivery of the preclinical package for Affitech’s anti VEGF antibody AT001/r84 to its Russian collaboration partner IBC Generium, who will use the package ...


Affitech A/S strengthens its IP portfolio on anti-VEGF antibody AT001/r84


Affitech A/S announced that the U.S. Patent and Trademark Office (USPTO) has granted Affitech U.S. patent (no. 8,034,905) covering the Company’s anti-VEGF antibody drug candidate AT001/r84. The newly granted US patent is the first patent grant Affitech has received for this compound in a major ...


Affitech announces Management change: Managing Director Dr Martin Welschof will leave


Affitech A/S announced that Dr Martin Welschof, its Managing Director, will leave his position at the end of the year. The Board of Directors has accepted his resignation with effect from 31st December, 2011 and will consider potential candidates to succeed him during the coming weeks.Dr ...


Affitech A/S receives EUR 2.5 million license fee for development of new anti-VEGF antibody drug in Russia


Affitech A/S announced that IBC Generium has exercised the license to Affitech’s lead anti-VEGF antibody drug candidate AT001/r84. The license grant triggered a payment of Euro 2.5 million by IBC Generium to Affitech A/S and provides IBC Generium with the exclusive rights to develop and market ...


Affitech A/S signs research agreement with UT Southwestern to support further development of its lead antibody drug candidate AT001/r84


Affitech A/S announced that the Company has signed a sponsored research agreement with Dr. Rolf Brekken at the University of Texas Southwestern Medical Center, Dallas, USA to further understand the mechanism and potential differentiation of Affitech’s lead antibody drug candidate AT001/r84.The ...


Affitech A/S appoints Stig Jarle Pettersen Chief Financial Officer


Affitech A/S announced that Stig Jarle Pettersen (49) has been appointed CFO in Affitech A/S. Stig Jarle Pettersen will be a member of the Executive Management of Affitech A/S together with Managing Director Martin Welschof and Chief Scientific Officer Alexander ...


Affitech's lead drug candidate AT001/r84 potent on tumours in mice studies with limited induction of side effects


Affitech A/S announced that the Company's lead drug candidate r84, which may have therapeutic application against certain cancers, shows potent activity on tumours and does not induce significant side effects in mice. This is the conclusion of a study conducted by Rolf Brekken, University of ...


Affitech Announces Organisational Changes: CEO Replaced by COO


Affitech A/S announced organisational changes. CEO Dr Robert Burns is leaving the Company and will be replaced by Dr Martin Welschof as Managing Director of Affitech A/S. Affitech recently announced a Research and Development Collaboration and Licensing Agreement with Russian NTS Plus ...


Affitech Signs Strategic Alliance with Russian Biotech Partner


NauchTekhStroy Plus (NTS Plus), a newly formed joint venture subsidiary of Pharmstandard will conduct clinical development and registration of two Affitech antibodies for Russian and CIS markets. NTS Plus will pay €23 million in fees and advanced royalties to Affitech. Pharmstandard will ...


Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development


Affitech A/S announced that it has appointed two experienced biotech executives to head its management team. Dr Robert Burns, previously CEO of Celldex Therapeutics Inc., has assumed overall responsibility for Affitech as its new Chief Executive Officer. Dr Alexander Duncan, previously SVP ...


Page 1 From 2
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE